Clinical trial · no report yet · Phase 3
AcceleRET-Lung
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
- NCT04222972 ↗
- Terminated
- Hoffmann-La Roche
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- RET-fusion Non Small Cell Lung Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Diseases; Head and Neck Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue
- Interventions
- Pralsetinib; Carboplatin; Cisplatin; Pemetrexed; Pembrolizumab; Gemcitabine; Paclitaxel; Nab-Paclitaxel
- Arms
- Pralsetinib · Experimental
- Platinum-based chemotherapy with or without pembrolizumab · Active comparator
- Enrollment
- 223
- Primary outcomes
- Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS)
- Sponsor
- Hoffmann-La Roche
- Start
- Jul 24, 2020
- Primary completion
- Jan 27, 2025
- Results posted
- Yes
- Registry record
- NCT04222972 · updated Mar 5, 2026